Skip to main content
Log in

Acetylcysteine

Fluimucil, Mucomyst, N-Acetylcysteine, NAC, NSC 111180

  • Section 2: Depatitis C
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Beloqui O, Prieto J, Sußrez M, et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis-C: a pilot study. J Interferon Res 1993 Aug; 13: 279–82

    Article  PubMed  CAS  Google Scholar 

  2. Gomez M, Clotet B, Ruiz L, et al. Efficacy of high dose, oral N-acetylcysteine, associated with ZDV, in a double blind, placebo controlled study, in PWAs with CD4 less than 250/mm3. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct-4–7; Orlando, 56

    Google Scholar 

  3. Tripi S, Di Gaetano G, Soresi M, et al. Acetylcysteine therapy for chronic hepatitis C: are its effects synergistic with interferon alpha? A pilot study. Clin Drug Invest 1998 Oct; 16: 297–302

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Acetylcysteine. Drugs R&D 2, 265–266 (1999). https://doi.org/10.2165/00126839-199902040-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902040-00011

Keywords

Navigation